Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Recent Phase 3 trial results for Icotrokinra (JNJ-2113), an investigational oral peptide from Johnson & Johnson, have shown the drug’s potential to offer significant relief for patients suffering from ...

Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...

In people with psoriasis, immune cells secrete inflammatory biomarkers that cause the skin to overproduce keratinocytes and create plaques on the skin that are characteristic of plaque psoriasis, ...

Positive, phase 3 data for once-daily JNJ-2113 (icotrokinra) has been announced by Protagonist Therapeutics in collaboration with Johnson & Johnson that demonstrated "significant" skin clearance ...

The study was conducted among patients with plaque psoriasis affecting special areas such as the scalp, genitals and/or hands ...

"Plaque psoriasis often affects patients more severely than can be measured by body surface area alone, particularly for those with manifestations in difficult-to-treat areas like the scalp," she ...

Folliculitis is often caused by an infection in the hair follicles of the scalp or on shaved regions of the body ... Spots on the upper and lower limbs are likely. Following plaque psoriasis, guttate ...

Credit: Getty Images Researchers evaluated the efficacy and safety of deucravacitinib for the treatment of moderate to severe scalp psoriasis. Deucravacitinib was safe and effective for treating ...